{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:10:23Z","timestamp":1792509023782,"version":"4.5.0"},"reference-count":50,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2024,10,20]],"date-time":"2024-10-20T00:00:00Z","timestamp":1729382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Immune checkpoint inhibitor (ICI) therapy is becoming the standard of care for the treatment of advanced non-small-cell lung cancer. However, T-cell activation by ICIs frequently induces a flare-up of preexisting autoimmune diseases such as rheumatoid arthritis (RA). Janus kinase (JAK) inhibitors are increasingly used in the treatment of RA, but they could interfere with the efficacy of ICIs by inhibiting interferon signaling. Case Report: Here, we describe a case in which upadacitinib, a JAK1-selective inhibitor, was used to manage a severe RA flare-up occurring during ICI therapy with pembrolizumab, an anti-programmed cell death protein-1 antibody. A 54-year-old man with RA was diagnosed with grade IV lung squamous cell carcinoma. The patient had maintained RA remission for 4 years at the time of lung cancer diagnosis. After seven cycles of pembrolizumab therapy, the size of the primary tumor was markedly reduced, but a severe RA flare-up and organizing pneumonia (OP)-like pulmonary lesions occurred. Considering the severity of the flare-up, pembrolizumab was discontinued. Upadacitinib induced swift recovery from the RA flare-up and OP. Eleven months after the last pembrolizumab use, almost all metastatic lesions in the body had disappeared. We did not observe recurrence of lung cancer for more than 1 year during upadacitinib therapy. Conclusions: Upadacitinib could be a safe and effective option to treat severe RA flare-ups occurring during anti-PD-1 ICI therapy.<\/jats:p>","DOI":"10.3390\/jcm13206257","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T10:49:22Z","timestamp":1729507762000},"page":"6257","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Use of Upadacitinib to Treat a Severe Flare-Up of Rheumatoid Arthritis During Anti-PD-1 Immune Checkpoint Inhibitor Therapy for Stage IV Squamous Cell Carcinoma of the Lung"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7972-4252","authenticated-orcid":false,"given":"Shunsuke","family":"Mori","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Clinical Research Center for Rheumatic Diseases, National Hospital Organization (NHO) Kumamoto Saishun Medical Center, Kohshi 861-1196, Kumamoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0516-8913","authenticated-orcid":false,"given":"Kazuyoshi","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, National Hospital Organization (NHO) Kumamoto Saishun Medical Center, Kohshi 861-1196, Kumamoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minori","family":"Shimamura","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, National Hospital Organization (NHO) Kumamoto Saishun Medical Center, Kohshi 861-1196, Kumamoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouhei","family":"Ohe","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, National Hospital Organization (NHO) Kumamoto Saishun Medical Center, Kohshi 861-1196, Kumamoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40744-017-0064-4","article-title":"Malignancy incidence, management, and prevention in patients with rheumatoid arthritis","volume":"4","author":"Wilton","year":"2017","journal-title":"Rheumatol. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.berh.2019.03.011","article-title":"Malignancy and rheumatoid arthritis: Epidemiology, risk factors and management","volume":"32","author":"Hyrich","year":"2018","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/BOR.0000000000000796","article-title":"Impact of rheumatoid arthritis and biologic and targeted synthetic disease modifying antirheumatic agents on cancer risk and recurrence","volume":"33","author":"Singh","year":"2021","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ccm.2019.10.001","article-title":"Lung cancer 2020: Epidemiology, etiology, and prevention","volume":"41","author":"Bade","year":"2020","journal-title":"Clin. Chest Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e002465","DOI":"10.1136\/rmdopen-2022-002465","article-title":"Risk of lung cancer in rheumatoid arthritis and in relation to autoantibody positivity and smoking","volume":"8","author":"Chatzidionysiou","year":"2022","journal-title":"RMD Open"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Choi, H.G., Kang, H.S., Lim, H., Kim, J.H., Kim, J.H., Cho, S.J., Nam, E.S., Min, K.W., Park, H.Y., and Kim, N.Y. (2022). Potential cancer risk in patients with rheumatoid arthritis: A longitudinal Korean population-based analysis. J. Pers. Med., 12.","DOI":"10.3390\/jpm12060965"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1002\/ijc.34606","article-title":"Large-scale real-world data analyses of cancer risks among patients with rheumatoid arthritis","volume":"153","author":"Wang","year":"2023","journal-title":"Int. J. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"100768","DOI":"10.1016\/j.lanepe.2023.100768","article-title":"Risk of cancer for patients with rheumatoid arthritis versus general population: A national claims database cohort study","volume":"35","author":"Beydon","year":"2023","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jtho.2023.10.006","article-title":"Rheumatoid arthritis and risk of lung Cancer: A nationwide cohort study","volume":"19","author":"Cho","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/acr.25053","article-title":"A narrowing mortality gap: Temporal trends of cause-specific mortality in a national matched cohort study in US veteranswith rheumatoid arthritis","volume":"75","author":"Johnson","year":"2023","journal-title":"Arthritis Care Res."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Mori, S., Ueki, Y., Hasegawa, M., Nakamura, K., Nakashima, K., Hidaka, T., Ishii, K., Kobayashi, H., and Miyamura, T. (2024). Impact of combined pulmonary fibrosis and emphysema on lung cancer risk and mortality in rheumatoid arthritis: A multicenter retrospective cohort study. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0298573"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Mori, S., Hasegawa, M., Sakai, F., Nakashima, K., and Nakamura, K. (2024). Incidence of and predictive factors for lung cancer in patients with rheumatoid arthritis: A retrospective long-term follow-up study. Mod. Rheumatol., roae084.","DOI":"10.1093\/mr\/roae084"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Mamdani, H., Matosevic, S., Khalid, A.B., Durm, G., and Jalal, S.I. (2022). Immunotherapy in lung cancer: Current landscape and future directions. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.823618"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Brahmer","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41584-022-00841-0","article-title":"Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases","volume":"18","author":"Tison","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Onoi, K., Chihara, Y., Uchino, J., Shimamoto, T., Morimoto, Y., Iwasaku, M., Kaneko, Y., Yamada, T., and Takayama, K. (2020). Immune checkpoint inhibitors for lung cancer treatment: A review. J. Clin. Med., 9.","DOI":"10.3390\/jcm9051362"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Tang, S., Qin, C., Hu, H., Liu, T., He, Y., Guo, H., Yan, H., Zhang, J., Tang, S., and Zhou, H. (2022). Immune checkpoint inhibitors in non-small cell lung cancer: Progress, challenges, and prospects. Cells, 11.","DOI":"10.3390\/cells11030320"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2145102","DOI":"10.1080\/21645515.2022.2145102","article-title":"Safety and efficacy of immune checkpoint inhibitors in advanced cancer patients with autoimmune disease: A meta-analysis","volume":"18","author":"Cai","year":"2022","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"114148","DOI":"10.1016\/j.ejca.2024.114148","article-title":"A systematic review and meta-analysis of observational studies and uncontrolled trials reporting on the use of checkpoint blockers in patients with cancer and pre-existing autoimmune disease","volume":"207","author":"Kachira","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7326\/M17-2073","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: A systematic review","volume":"168","author":"Shah","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"102687","DOI":"10.1016\/j.autrev.2020.102687","article-title":"Immune checkpoint inhibitors therapies in patients with cancer and preexisting autoimmune diseases: A meta-analysis of observational studies","volume":"19","author":"Xie","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Liu, X., Li, S., Ke, L., and Cui, H. (2024). Immune checkpoint inhibitors in cancer patients with rheumatologic preexisting autoimmune diseases: A systematic review and meta-analysis. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-12256-z"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.rdc.2024.01.001","article-title":"Pre-existing autoimmune diseases and immune checkpoint inhibitors for cancer treatment: Considerations about initiation, flares, immune-related adverse events, and cancer progression","volume":"50","author":"Sparks","year":"2024","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/JLB.5RI0218-084R","article-title":"Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs","volume":"104","author":"Gadina","year":"2018","journal-title":"J. Leukoc. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/ard-2023-223850","article-title":"Selectivity, efficacy and safety of JAKinibs: New evidence for a still evolving story","volume":"83","author":"Bonelli","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrc.2016.14","article-title":"Antitumour actions of interferons: Implications for cancer therapy","volume":"16","author":"Parker","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/s41577-018-0029-z","article-title":"IFNgamma: Signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy","volume":"18","author":"Ivashkiv","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"ref_30","first-page":"69","article-title":"Organizing pneumonia in rheumatoid arthritis patients: A case-based review","volume":"9","author":"Mori","year":"2015","journal-title":"Clin. Med. Insights Circ. Respir. Pulm. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"152335","DOI":"10.1016\/j.semarthrit.2023.152335","article-title":"Immunomodulator use, risk factors and management of flares, and mortality for patients with pre-existing rheumatoid arthritis after immune checkpoint inhibitors for cancer","volume":"64","author":"McCarter","year":"2024","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/RHU.0000000000001314","article-title":"Risk of toxicity after initiating immune checkpoint inhibitor treatment in patients with rheumatoid arthritis","volume":"27","author":"Efuni","year":"2021","journal-title":"J. Clin. Rheumatol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Dang, Q.M., Watanabe, R., Shiomi, M., Fukumoto, K., Nobashi, T.W., Okano, T., Yamada, S., and Hashimoto, M. (2023). Rheumatic immune-related adverse events due to immune checkpoint inhibitors: A 2023 update. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24065643"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/rheumatology\/kead448","article-title":"Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases","volume":"63","author":"Taylor","year":"2024","journal-title":"Rheumatology"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Owen, K.L., Brockwell, N.K., and Parker, B.S. (2019). JAK-STAT signaling: A double-edged sword of immune regulation and cancer progression. Cancers, 11.","DOI":"10.3390\/cancers11122002"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Shin","year":"2017","journal-title":"Cell Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.cell.2016.03.031","article-title":"Combination cancer therapies with immune checkpoint blockade: Convergence on interferon signaling","volume":"165","author":"Minn","year":"2016","journal-title":"Cell"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/cas.13424","article-title":"PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer","volume":"109","author":"Mimura","year":"2018","journal-title":"Cancer Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ccell.2023.12.013","article-title":"Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer","volume":"42","author":"Memon","year":"2024","journal-title":"Cancer Cell"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade","volume":"167","author":"Benci","year":"2016","journal-title":"Cell"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"eade8520","DOI":"10.1126\/science.ade8520","article-title":"JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma","volume":"384","author":"Zak","year":"2024","journal-title":"Science"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"eadf1329","DOI":"10.1126\/science.adf1329","article-title":"Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients","volume":"384","author":"Mathew","year":"2024","journal-title":"Science"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1158\/1078-0432.CCR-22-1931","article-title":"Gallium-68-labeled peptide PET quantifies tumor exposure of PD-L1 therapeutics","volume":"29","author":"Mishra","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e007535","DOI":"10.1136\/jitc-2023-007535","article-title":"Non-invasive PD-L1 quantification using [(18)F]DK222-PET imaging in cancer immunotherapy","volume":"11","author":"Mishra","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e238851","DOI":"10.1136\/bcr-2020-238851","article-title":"First use of tofacitinib to treat an immune checkpoint inhibitor-induced arthritis","volume":"14","author":"Murray","year":"2021","journal-title":"BMJ Case Rep."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1186\/s12967-024-05617-6","article-title":"Tofacitinib for the treatment of immune-related adverse events in cancer immunotherapy: A multi-center observational study","volume":"22","author":"Liu","year":"2024","journal-title":"J. Transl. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1136\/ard-2022-222543","article-title":"Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: Results from the open-label, randomised controlled ORAL Surveillance trial","volume":"82","author":"Curtis","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Harrington, R., Harkins, P., and Conway, R. (2023). Janus kinase inhibitors in rheumatoid arthritis: An update on the efficacy and safety of tofacitinib, baricitinib and upadacitinib. J. Clin. Med., 12.","DOI":"10.3390\/jcm12206690"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2169\/internalmedicine.9341-17","article-title":"Tofacitinib therapy for rheumatoid arthritis: A direct comparison study between biologic-na\u00efve and experienced patients","volume":"57","author":"Mori","year":"2018","journal-title":"Intern. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e001601","DOI":"10.1136\/rmdopen-2021-001601","article-title":"Tofacitinib versus tocilizumab in the treatment of biological-naive or previous biological-failure patients with methotrexate-refractory active rheumatoid arthritis","volume":"7","author":"Mori","year":"2021","journal-title":"RMD Open"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/20\/6257\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:16:56Z","timestamp":1760113016000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/20\/6257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,20]]},"references-count":50,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["jcm13206257"],"URL":"https:\/\/doi.org\/10.3390\/jcm13206257","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,20]]}}}